BioMarin Acquires Alesta Therapeutics for $275 Million to Expand Rare Disease Pipeline
BioMarin Pharmaceuticals (NASDAQ:BMRN) agreed to acquire Alesta Therapeutics in a deal valued at up to $490 million, with an upfront payment of $275 million and potential additional payments tied to development milestones. The acquisition targets ALE1, Alesta's lead clinical-stage candidate for hypophosphatasia (HPP), which could become the first oral treatment option for this rare genetic disorder currently managed through injectable therapies. The transaction is expected to close in Q3 2026 and will be funded entirely from BioMarin’s existing cash reserves. Alesta's non-AL1 assets are being spun off into a separate entity, with employees transferring accordingly. The deal has received board approval at both companies.
Tickers: $BMRN